Phase 3 N=203 Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy
Liver Transplantation
Primary: Calculated Glomerular Filtration Rate (cGFR) — 87.9; 84.1 mL/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=120 Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Clinical Success ITT — 32; 11 participants — p=<0.0001
Phase 3 N=6 High Dose Cyclophosphamide for Treatment of Scleroderma
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Phase 3 N=833 A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
Infection, Human Immunodeficiency Virus I
Primary: Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 c/mL at Week 48 — 88; 81 Percentage of participants — p=0.003
Phase 3 N=329 Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension
Pain, Postoperative · Bunion
Primary: SPID48 (Summed Pain Intensity Difference) — 114.9; 66.9 scores on a scale
Phase 3 N=135 Residual Effect of Chlorhexidine-alcohol Compared to Triclosan-alcohol
Infectious Diseases
Primary: Evaluate the Residual Effect of Chlorhexidine 2% / Isopropyl Alcohol 70% Administered Topically — 24; 48; 24 (CFU/cm2) — p=<0.05
Phase 3 N=1,412 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)
Measles · Mumps · Rubella
Primary: Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels >=5 gpELISA Units/mL — 97.3; 93.0 Percentage of participants — p=<0.001
Phase 3 N=99 Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After Six Weeks of Treatment — -0.060; 0.088; 0.088; 0.081 Liter — p=<0.0001
Phase 3 N=301 Safety and Efficacy of Albiglutide in Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 — -0.05; -0.81 Percentage of HbA1c in the blood — p=<0.0001
Phase 3 N=465 Diltiazem Hydrochloride Cream for Anal Fissure
Chronic Anal Fissure
Primary: Change From Baseline in Average of Worst Anal Pain Associated With or Following Defaecation for Week 4 (for the 7 Treatment Days Immediately Preceding the Week 4 Visit)…
Phase 3 N=663 A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 — 0.33; -0.80; -0.55 Percentage of HbA1c in the blood — p=<0.0001
Phase 3 N=27 Study to Assess the Efficacy and Safety of Potassium Clavulanate/Amoxicillin in Children With Acute Bacterial Rhinosinusitis
Sinusitis, Acute
Primary: Number of Participants With a Clinical Outcome of "Cure" at Test of Cure (TOC: Day 15) — 23; 3; 0 Participants
Phase 3 N=943 Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)
Menopause · Vasomotor Symptoms
Primary: Change From Baseline in Average Daily Frequency of Vasomotor Symptoms (Frequency Score A) at Week 4 — -3.9; -5.6; -6.0; -6.0 Number of events — p=<0.01
Phase 3 N=122 A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After Six Weeks of Treatment — -0.008; 0.189; 0.213; 0.213 Liter — p=<0.0001
Phase 3 N=48 Effectiveness of Mirror Therapy in Stroke Patients With Unilateral Neglect - A Randomized Controlled Trial
Hemispatial Neglect
Primary: Change From Baseline in Star Cancellation Test Scores at 1,3, and 6 Months — 17.88; 18.20; 20.03; 5.90 units on a scale — p=0.77